title: Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
authors.affiliation: Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Mohamad Bassam
authors.initials: MB
authors.lastname: Sonbol
authors.forename: Hemang
authors.initials: H
authors.lastname: Yadav
authors.forename: Rakhee
authors.initials: R
authors.lastname: Vaidya
authors.forename: Vishal
authors.initials: V
authors.lastname: Rana
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Witzig
mesh_terms: D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000188:drug therapy / Q000628:therapy; D000975:Antioxidants / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008708:Methemoglobinemia / Q000139:chemically induced* / Q000188:drug therapy / Q000628:therapy; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D019653:Myeloablative Agonists / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000517:prevention & control*; D014503:Urate Oxidase / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D019653:Myeloablative Agonists; C469709:rasburicase; D003520:Cyclophosphamide; D014503:Urate Oxidase; D001205:Ascorbic Acid